Payment overview · 2025
General Payments
$1,880.70
82 reported records · 16 companies
Healthcare provider profile · identity verified
Riley Jo Larner
Physician Assistants & Advanced Practice Nursing Providers|Physician Assistant · NOVI, MI · NPI 1194485904
Verified facts
What the public records show
CMS Open Payments records show Riley Jo Larner received $1,880.70 in general payments during 2025 across 82 reported records.
ABBVIE INC. accounted for 21.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 25 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Farxiga by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Trelegy Ellipta by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $396.63 | 21.1% | 19 | 2025 |
| Madrigal Pharmaceuticals | Unresolved — no canonical attribution shown | $350.11 | 18.6% | 12 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $297.96 | 15.8% | 12 | 2025 |
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $296.72 | 15.8% | 12 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $127.75 | 6.8% | 6 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $88.57 | 4.7% | 4 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $65.93 | 3.5% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $64.25 | 3.4% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $51.64 | 2.8% | 3 | 2025 |
| Regeneron Healthcare Solutions, Inc. | Unresolved — no canonical attribution shown | $43.30 | 2.3% | 2 | 2025 |
| VIVUS LLC | Unresolved — no canonical attribution shown | $19.01 | 1.0% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $18.75 | 1.0% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $16.47 | 0.9% | 1 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $14.80 | 0.8% | 1 | 2025 |
| Solventum Corporation | Unresolved — no canonical attribution shown | $14.66 | 0.8% | 1 | 2025 |
| TerSera Therapeutics LLC | Unresolved — no canonical attribution shown | $14.15 | 0.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,796.70 | 81 |
| Education | $84.00 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REZDIFFRA Normalized: rezdiffra |
Drug | Madrigal Pharmaceuticals | $350.11 | 12 | 2025 |
Source payment records
|
|||||
| SKYRIZI Normalized: skyrizi |
Biological | ABBVIE INC. | $319.87 | 15 | 2025 |
Source payment records
|
|||||
| TREMFYA Normalized: tremfya |
Drug | Janssen Biotech, Inc. | $296.72 | 12 | 2025 |
Source payment records
|
|||||
| RINVOQ Normalized: rinvoq |
Biological | ABBVIE INC. | $263.41 | 11 | 2025 |
Source payment records
|
|||||
| ENTYVIO Normalized: entyvio |
Biological | Takeda Pharmaceuticals U.S.A., Inc. | $240.60 | 10 | 2025 |
Source payment records
|
|||||
| VELSIPITY Normalized: velsipity |
Drug | PFIZER INC. | $112.93 | 5 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $88.57 | 4 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $76.76 | 4 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $76.76 | 4 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $65.93 | 3 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $64.25 | 3 | 2025 |
Source payment records
|
|||||
| EOHILIA Normalized: eohilia |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $57.36 | 2 | 2025 |
Source payment records
|
|||||
| DUPIXENT Normalized: dupixent |
Biological | Regeneron Healthcare Solutions, Inc. | $43.30 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $29.09 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $22.55 | 1 | 2025 |
Source payment records
|
|||||
| XELJANZ Normalized: xeljanz |
Drug | PFIZER INC. | $21.67 | 1 | 2025 |
Source payment records
|
|||||
| QSYMIA Normalized: qsymia |
Drug | VIVUS LLC | $19.01 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $18.75 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $18.75 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $16.47 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $14.82 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $14.82 | 1 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $14.80 | 1 | 2025 |
Source payment records
|
|||||
| ACTIV.A.C. Normalized: activ a c |
Device | Solventum Corporation | $14.66 | 1 | 2025 |
Source payment records
|
|||||
| Xermelo Normalized: xermelo |
Drug | TerSera Therapeutics LLC | $14.15 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 36 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 22 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 40 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
22 | 12 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
40 | 22 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
36 | 18 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 189 | 101 |
| Atorvastatin Calcium | Atorvastatin Calcium | 185 | 108 |
| Lisinopril | Lisinopril | 154 | 82 |
| Metoprolol Succinate | Metoprolol Succinate | 95 | 50 |
| Levothyroxine Sodium | Levothyroxine Sodium | 89 | 45 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 82 | 34 |
| Metformin Hcl | Metformin Hcl | 81 | 49 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 74 | 17 |
| Pantoprazole Sodium | Pantoprazole Sodium | 67 | 32 |
| Jardiance | Empagliflozin | 65 | 31 |
| Omeprazole | Omeprazole | 62 | 27 |
| Losartan Potassium | Losartan Potassium | 61 | 34 |
| Gabapentin | Gabapentin | 60 | 21 |
| Simvastatin | Simvastatin | 52 | 26 |
| Sertraline Hcl | Sertraline Hcl | 51 | 24 |
| Metoprolol Tartrate | Metoprolol Tartrate | 48 | 23 |
| Trulicity | Dulaglutide | 47 | 14 |
| Trazodone Hcl | Trazodone Hcl | 45 | 12 |
| Hydrochlorothiazide | Hydrochlorothiazide | 43 | 22 |
| Furosemide | Furosemide | 40 | 26 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 40 | 22 |
| Famotidine | Famotidine | 39 | 20 |
| Tizanidine Hcl | Tizanidine Hcl | 37 | 21 |
| Eliquis | Apixaban | 36 | 18 |
| Hydralazine Hcl | Hydralazine Hcl | 36 | 19 |
| Alprazolam | Alprazolam | 34 | 16 |
| Potassium Chloride | Potassium Chloride | 34 | 13 |
| Carvedilol | Carvedilol | 32 | 11 |
| Fluticasone Propionate | Fluticasone Propionate | 31 | 17 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 30 | 17 |
| Januvia | Sitagliptin Phosphate | 25 | 13 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 25 | 12 |
| Montelukast Sodium | Montelukast Sodium | 25 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 23 | 15 |
| Buspirone Hcl | Buspirone Hcl | 22 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 22 | 14 |
| Farxiga | Dapagliflozin Propanediol | 22 | 12 |
| Ventolin Hfa | Albuterol Sulfate | 22 | suppressed |
| Ibuprofen | Ibuprofen | 21 | 11 |
| Mirtazapine | Mirtazapine | 21 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 21 | 14 |
| Allopurinol | Allopurinol | 20 | 11 |
| Ezetimibe | Ezetimibe | 18 | suppressed |
| Glipizide | Glipizide | 18 | 12 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 18 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 18 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 18 | suppressed |
| Methylprednisolone | Methylprednisolone | 17 | 15 |
| Dicyclomine Hcl | Dicyclomine Hcl | 16 | suppressed |
| Loperamide | Loperamide Hcl | 15 | suppressed |
| Mounjaro | Tirzepatide | 15 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 15 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 14 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 14 | suppressed |
| Nifedipine Er | Nifedipine | 14 | 12 |
| Nystatin | Nystatin | 14 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 14 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 13 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 13 | suppressed |
| Alcohol Swabs | Alcohol Antiseptic Pads | 12 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 12 | suppressed |
| Pregabalin | Pregabalin | 12 | suppressed |
| Bumetanide | Bumetanide | 11 | suppressed |
| Clotrimazole | Clotrimazole | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,880.70 · 82 records | ABBVIE INC. | ACTIV.A.C., AREXVY, BREZTRI, CREON, Cologuard Collection Kit, DUPIXENT, ELIQUIS, ENTYVIO, EOHILIA, FARXIGA, IBSRELA, LINZESS, NURTEC ODT, QSYMIA, REZDIFFRA, RINVOQ, SKYRIZI, TRELEGY ELLIPTA, TREMFYA, VELSIPITY, Wegovy, XELJANZ, XIFAXAN, Xermelo, ZENPEP | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error